thalidomide has been researched along with Substance Withdrawal Syndrome in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Morphine dependence and the subsequent withdrawal syndrome restrict its clinical use in management of chronic pain." | 7.88 | Thalidomide attenuates development of morphine dependence in mice by inhibiting PI3K/Akt and nitric oxide signaling pathways. ( Dehpour, AR; Ejtemaei-Mehr, S; Jahanabadi, S; Khan, MI; Momeny, M; Ostadhadi, S; Sameem, B; Zarrinrad, G, 2018) |
| "Morphine dependence and the subsequent withdrawal syndrome restrict its clinical use in management of chronic pain." | 3.88 | Thalidomide attenuates development of morphine dependence in mice by inhibiting PI3K/Akt and nitric oxide signaling pathways. ( Dehpour, AR; Ejtemaei-Mehr, S; Jahanabadi, S; Khan, MI; Momeny, M; Ostadhadi, S; Sameem, B; Zarrinrad, G, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, MI | 1 |
| Momeny, M | 1 |
| Ostadhadi, S | 1 |
| Jahanabadi, S | 1 |
| Ejtemaei-Mehr, S | 1 |
| Sameem, B | 1 |
| Zarrinrad, G | 1 |
| Dehpour, AR | 1 |
| MILLER, JM | 1 |
| GINSBERG, M | 1 |
| MCELFATRICK, GC | 1 |
| SHONBERG, IL | 1 |
| Frederickson, RC | 1 |
| Slater, IH | 1 |
| Dusenberry, WE | 1 |
| Hewes, CR | 1 |
| Jones, GT | 1 |
| Moore, RA | 1 |
| Cooper, SJ | 1 |
| Kelsey, FO | 1 |
1 review available for thalidomide and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Drugs in pregnancy and their effects on pre- and postnatal development.
Topics: Abnormalities, Drug-Induced; Alkylating Agents; Animals; Anticonvulsants; Antimetabolites; Central N | 1973 |
4 other studies available for thalidomide and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Thalidomide attenuates development of morphine dependence in mice by inhibiting PI3K/Akt and nitric oxide signaling pathways.
Topics: Animals; Cell Line, Tumor; Central Nervous System Agents; Hippocampus; Humans; Male; Mice; Morphine; | 2018 |
The use of contergan-268 in the treatment of the withdrawal syndrome in chronic alcoholism.
Topics: Alcoholism; Anesthesia; Humans; Hypnotics and Sedatives; Substance Withdrawal Syndrome; Thalidomide | 1960 |
A comparison of thalidomide and pentobarbital - new methods for identifying novel hypnotic drugs.
Topics: Animals; Avoidance Learning; Canaries; Cats; Conditioning, Operant; Drug Evaluation, Preclinical; Hu | 1977 |
Poisoned people: psychotropic drugs in pregnancy: morphological and psychological adverse effects on offspring.
Topics: Abnormalities, Drug-Induced; Alcoholism; Behavior; Female; Fetal Alcohol Spectrum Disorders; Fetus; | 1978 |